ImmunityBio (IBRX) Change in Account Payables (2014 - 2026)
ImmunityBio (IBRX) reported Change in Account Payables of $3.9 million for Q1 2026, down 39.42% year-over-year from $6.4 million in Q1 2025, and up 298.47% quarter-over-quarter from $979000.0 in Q4 2025.
ImmunityBio (IBRX) Change in Account Payables (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 13 years of Change in Account Payables data on file, last reported at $3.9 million in Q1 2026.
- Change in Account Payables for Q1 2026 came in at $3.9 million, down 39.42% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.7 million (down 161.8% YoY), and the FY2025 annual result was -$190000.0, up 94.0% from the prior year.
- Change in Account Payables advanced to $3.9 million in Q1 2026 per IBRX's latest filing, from $979000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $6.4 million in Q1 2025 and troughed at -$8.9 million in Q3 2024.
- A 5-year average of $121647.1 and a median of $668000.0 in 2023 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2023 and 2024: Change in Account Payables sank 758.35% in 2023, then jumped 545.81% in 2024.
- A 5-year view of Change in Account Payables shows it stood at $437000.0 in 2022, then slumped by 758.35% to -$2.9 million in 2023, then fell by 11.71% to -$3.2 million in 2024, then soared by 130.46% to $979000.0 in 2025, then soared by 298.47% to $3.9 million in 2026.
- Business Quant data shows IBRX's Change in Account Payables at $3.9 million in Q1 2026, $979000.0 in Q4 2025, and -$1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | ImmunityBio | 7.55 Bn | 7.17 Bn | 43.97 Mn | 3.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.90 Mn |
| Mar 31, 2026 | 3.90 Mn |
| Dec 31, 2025 | 979,000.00 |
| Dec 31, 2025 | 979,000.00 |
| Sep 30, 2025 | -1.39 Mn |
| Sep 30, 2025 | -1.39 Mn |
| Jun 30, 2025 | -6.22 Mn |
| Jun 30, 2025 | -6.22 Mn |
| Mar 31, 2025 | 6.44 Mn |
| Mar 31, 2025 | 6.44 Mn |
| Dec 31, 2024 | -3.21 Mn |
| Dec 31, 2024 | -3.21 Mn |
| Sep 30, 2024 | -8.92 Mn |
| Sep 30, 2024 | -8.92 Mn |
| Jun 30, 2024 | 4.66 Mn |
| Jun 30, 2024 | 4.66 Mn |
| Mar 31, 2024 | 4.31 Mn |
| Mar 31, 2024 | 4.31 Mn |
| Dec 31, 2023 | -2.88 Mn |
| Dec 31, 2023 | -2.88 Mn |